^
Association details:
| Biomarker: | ALK C1156Y + ALK L1198F |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Excerpt:
We detected the double mutation (ALK C1156Y–L1198F) in the lorlatinib-resistant sample and the single ALK C1156Y mutation in the crizotinib-resistant sample.
DOI:
10.1056/NEJMoa1508887
